Centessa Pharmaceuticals plc (NASDAQ:CNTA) Short Interest Update

Centessa Pharmaceuticals plc (NASDAQ:CNTA) was the target of a significant decline in short interest during the month of January. As of January 31st, there was short interest totalling 3,050,000 shares, a decline of 7.3% from the January 15th total of 3,290,000 shares. Based on an average trading volume of 678,600 shares, the short-interest ratio is currently 4.5 days. Currently, 3.4% of the company’s stock are sold short.

Centessa Pharmaceuticals Trading Down 3.1 %

Shares of Centessa Pharmaceuticals stock traded down $0.55 during trading hours on Monday, hitting $17.07. The company’s stock had a trading volume of 2,100,866 shares, compared to its average volume of 556,728. Centessa Pharmaceuticals has a twelve month low of $7.75 and a twelve month high of $19.09. The firm has a fifty day moving average of $16.75 and a 200-day moving average of $15.73. The stock has a market cap of $2.25 billion, a price-to-earnings ratio of -11.16 and a beta of 1.53. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52.

Insider Transactions at Centessa Pharmaceuticals

In related news, CEO Saurabh Saha sold 87,496 shares of Centessa Pharmaceuticals stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $18.46, for a total transaction of $1,615,176.16. Following the completion of the sale, the chief executive officer now owns 575,661 shares of the company’s stock, valued at $10,626,702.06. The trade was a 13.19 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Gregory M. Weinhoff sold 10,000 shares of Centessa Pharmaceuticals stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $17.66, for a total value of $176,600.00. Following the sale, the insider now directly owns 183,266 shares of the company’s stock, valued at $3,236,477.56. This trade represents a 5.17 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 452,652 shares of company stock worth $7,800,532. Insiders own 11.59% of the company’s stock.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. raised its position in Centessa Pharmaceuticals by 47.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock valued at $40,000 after purchasing an additional 826 shares in the last quarter. GAMMA Investing LLC raised its position in Centessa Pharmaceuticals by 29.1% in the 4th quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock valued at $64,000 after purchasing an additional 865 shares in the last quarter. Barclays PLC raised its position in Centessa Pharmaceuticals by 1,414.9% in the 4th quarter. Barclays PLC now owns 5,302 shares of the company’s stock valued at $89,000 after purchasing an additional 4,952 shares in the last quarter. BNP Paribas Financial Markets acquired a new stake in Centessa Pharmaceuticals in the 4th quarter valued at about $162,000. Finally, OMERS ADMINISTRATION Corp acquired a new stake in Centessa Pharmaceuticals in the 4th quarter valued at about $171,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have issued reports on CNTA. TD Cowen began coverage on Centessa Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating for the company. Guggenheim restated a “buy” rating on shares of Centessa Pharmaceuticals in a research report on Monday, February 10th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $25.83.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.